Pfizer’s effort to join the weight-loss drug craze just hit a major setback. Patients are quitting its trial after experiencing unpleasant side effects. We’ll bring you the details, and the stock reaction.

Plus, our Retail Ecosystem series concludes with a look at luxury stocks. Is the high-end consumer still buying, or spending money elsewhere on things like experiences? We’ll ask an industry insider.